PF-Atlas › Treatments › YAP/TAZ Inhibition

YAP/TAZ Inhibition

Blocks mechanosensing amplification loop — breaks stiffness-to-fibrosis cycle

Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 3 (Preclinical)
Mechanism class
Blocks mechanosensing amplification loop — breaks stiffness-to-fibrosis cycle
Timeline
3-5 years
Risk profile
Medium
Developer
Multiple
Key researchers
S. Bhatt

Overview

Reverses established fibrosis in mice. YAP/TAZ activation by matrix stiffness is self-amplifying. Verteporfin is FDA-approved for other uses.

How YAP/TAZ Inhibition fits into IPF treatment

YAP/TAZ Inhibition is classified as Level 3 (Preclinical) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:

YAP drug profileBlocks mechanosensing amplification loop — breaks stiffness-to-fibrosis cycleClinical trialsDrug pipelineResearch

Other IPF treatments

Nerandomilast / JascaydInhaled Treprostinil / TyvasoAdmilparant / BMS-986278Rentosertib / ISM001-055AI Knowledge GraphuPAR-CAR-T Senolytic Immunotherapy
Medical disclaimer. This page summarizes published research and PF-Atlas model output about YAP/TAZ Inhibition for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.